A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION

A5142/PH III/洛匹那韦/利托那韦 EFAVIR 用于 HIV-1 感染的初始治疗

• 批准号: 7604175
• 负责人: ROY M. GULICK
• 金额: $ 0.03万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604175
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Failure; Funding; Grant; HIV-1; Infection; Institution; Lamivudine; Lopinavir/Ritonavir; Randomized; Research; Research Personnel; Resources; Source; Time; Toxic effect; Treatment Protocols; United States National Institutes of Health; Zidovudine; efavirenz

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to compare the time to virologic failure pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC, and to compare the time to regimen completion pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 The primary objective of this study is to compare the time to virologic failure pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC, and to compare the time to regimen completion pairwise between the三个治疗组：Lopinavir/Ritonavir Plus Efavirenz，Lopinavir/Ritonavir Plus D4T扩展释放（或Zidovudine）加上3TC，Efavirenz加上D4T Extended earlive（或Zidovudine）加3TC。治疗方法的完成将定义为对初始随机治疗方案的任何组成部分的病毒学衰竭或与毒性相关的停用。